Patent intelligence · WO
WO 2026030375
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION
Patent details — WO 2026030375
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Feb 5, 2026
- Expiration
- Jan 31, 2046
- Applicant
- GENZYME CORP [US]
- CPC classes
- A61K 47/ 68 A I, A61K/317105, A61K/476849, A61K/476889
Quick answer
WO 2026030375 (NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION) is held by GENZYME CORP [US]. Status: granted. Granted Feb 5, 2026. Expires Jan 31, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- GENZYME CORP [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 47/ 68 A I, A61K/317105, A61K/476849, A61K/476889, A61K/476913, A61K/476929
More from GENZYME CORP [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2026078159
AGENTS D'ACTIVATION DE CELLULES IMMUNITAIRES ET PROCÉDÉS LES COMPRENANT
granted -
WO 2025262150
MOLÉCULES DE RECRUTEMENT D'ANTICORPS
granted -
AR 133055
DOMINIOS VARIABLES ÚNICOS DE INMUNOGLOBULINA DIRIGIDOS A PD-L1
granted -
MX 2025007399
PROTEIN-BASED CONJUGATION CARRIERS
granted -
WO 2025133166
VÉHICULES À BASE DE PROTÉINES POUR CONJUGAISON D'AMINE SPÉCIFIQUE À UN SITE
granted -
WO 2025133252
DOMAINES VARIABLES UNIQUES D'IMMUNOGLOBULINE CIBLANT CEACAM5
granted -
WO 2025133253
EXCIPIENTS DE CONJUGAISON PROTÉINIQUES POUR ADMINISTRATION INTRANUCLÉAIRE
granted
Frequently asked questions
What is US patent 2026030375?
WO 2026030375 (NANOPARTICULES LIPIDIQUES ET LEURS PROCÉDÉS DE FABRICATION ET D'UTILISATION) is held by GENZYME CORP [US]. Status: granted. Granted Feb 5, 2026. Expires Jan 31, 2046 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026030375?
GENZYME CORP [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2026030375 expire?
Our index shows an expiration date of Jan 31, 2046 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.